This session will focus on malignancies of undefined primary origin (MUO) and cancers of unknown primary (CUP). It will discuss the increasing role of acute oncology and CUP teams in managing these patients in the UK and the challenges faced by the clinical community. It will provide an overview of current research in this area and describe the opportunities to manage this challenging group of patients. Attendees will be able to learn more about prognostic and predictive biomarkers for CUP and MUO, to help manage clinical pathways and patient expectations. They will learn about UK translational research and clinical trials and how these might lead to improvements in patient treatment opportunities. By the end of the session, delegates will have a better understanding of this group of patients and under-explored area of research and learn ways in which they could collaborate with other researchers interested in CUP and MUO.
- Dr Kai-Keen Shiu, UCL Cancer Institute, UK
- Dr Sally Clive, NHS Lothian, UK
- Dr Natalie Cook, The Christie NHS Foundation Trust, UK
- Mr John Symons, CUP Foundation – Jo’s friends, UK
- Ms Gillian Knowles, NHS Lothian, UK
1 category 1 (external) CPD for this session has been approved by the Federation of the Royal Colleges of Physicians. CPD Certificates will be sent to delegates automatically up to 10 days after the event date.
Who should attend?
Doctors and healthcare professionals involved in managing patients with MUO and CUP and those interested in CUP research and trials. This would include acute oncology teams, CUP clinicians, research support staff, scientists, students patients and carers.